NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.
The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.